-
Second Biosimilar Tocilizumab Injection approved for marketing
2023-01-18
Recently, the Tocilizumab Injection (Chinese trade name: 安维泰) of Livzon Pharmaceutical Group Inc. is approved for marketing by China NMPA. This drug is the second Tocilizumab Injection biosimilar approved in China, which is indicated for rheumatoid arthritis.
-
Biosimilar Tocilizumab Injection approved for marketing
2023-01-16
Recently, the Tocilizumab Injection (Chinese trade name:施瑞立) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
-
Hemodialysis urea clearance calculation software approved for marketing
2023-02-27
Recently, the innovative product Hemodialysis urea clearance calculation software of Beijing IfmSoft Co., Ltd is approved by China NMPA.
-
Hybrid Closed Loop Insulin Delivery System approved for marketing
2023-02-27
Recently, the innovative product Hybrid Closed Loop Insulin Delivery System ( MiniMed 670G BLE) of Medtronic MiniMed is approved by China NMPA.
-
Leritrelvir Tablets for treating COVID-19 infection approved with conditions for marketing
2023-03-23
Recently, the class 1 innovative drug Leritrelvir Tablets (Chinese trade name: 乐睿灵) of Guangdong Raynovent Biotech Co., Ltd is approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Third China domestic ECMO products approved for marketing
2023-02-23
On February 23, 2023, the Extracorporeal Membrane Oxygenation auxiliary device and centrifugal pump head of Jiangsu STMed Technology Inc. is approved with conditions through emergency review by China NMPA.
